title: Endothelial-specific CYP4A2 overexpression leads to renal injury and hypertension via increased production of 20-HETE.
abstract: We have previously reported that adenoviral-mediated delivery of cytochrome P-450 (CYP) 4A2, which catalyzes the synthesis of 20-hydroxyeicosatetraenoic acid (20-HETE), results in endothelial dysfunction and hypertension in Sprague-Dawley (SD) rats (Wang JS, Singh H, Zhang F, Ishizuka T, Deng H, Kemp R, Wolin MS, Hintze TH, Abraham NG, Nasjletti A, Laniado-Schwartzman M. Circ Res 98: 962-969, 2006). In this study, we targeted the vascular endothelium by using a lentivirus construct expressing CYP4A2 under the control of the endothelium-specific promoter VE-cadherin (VECAD-4A2) and examined the effect of long-term CYP4A2 overexpression on blood pressure and kidney function in SD rats. A bolus injection of VECAD-4A2 increased blood pressure (P < 0.001) by 26, 36, and 30 mmHg 10, 20, and 30 days postinjection, respectively. Arteries from VECAD-4A2-transduced rats produced increased levels of 20-HETE (P < 0.01), expressed lower levels of endothelial nitric oxide synthase (eNOS) and phosphorylated eNOS (p-eNOS) (P < 0.05), generated higher levels of superoxide anion, and displayed decreased relaxing responsiveness to acetylcholine (P < 0.05). Proteinuria increased by twofold in VECAD-4A2-transduced rats compared with controls. Treatment of VECAD-4A2-transduced rats with HET0016, an inhibitor of 20-HETE biosynthesis, not only attenuated the increase in blood pressure (P < 0.05) but also improved vascular function (acetylcholine-induced relaxations) and reduced plasma creatinine and proteinuria. HET0016 treatment decreased oxidative stress and increased the phosphorylated state of key proteins that regulate endothelial function, including eNOS, AKT, and AMPK. Collectively, these findings demonstrate that augmentation of vascular endothelial 20-HETE levels results in hypertension, endothelial dysfunction, and renal injury, which is offset by HET0016 through a reduction in vascular 20-HETE coupled with a lessening of oxidative stress and the amplification of pAKT, pAMPK, and p-eNOS levels leading to normalization of endothelial responses.
authors.affiliation: Dept. of Pharmacology, New York Medical College, Valhalla, NY, USA.
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Inoue
authors.forename: Komal
authors.initials: K
authors.lastname: Sodhi
authors.forename: Nitin
authors.initials: N
authors.lastname: Puri
authors.forename: Katherine H
authors.initials: KH
authors.lastname: Gotlinger
authors.forename: Jiang
authors.initials: J
authors.lastname: Cao
authors.forename: Rita
authors.initials: R
authors.lastname: Rezzani
authors.forename: John R
authors.initials: JR
authors.lastname: Falck
authors.forename: Nader G
authors.initials: NG
authors.lastname: Abraham
authors.forename: Michal
authors.initials: M
authors.lastname: Laniado-Schwartzman
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000378:metabolism; D000109:Acetylcholine; D000818:Animals; D015703:Antigens, CD / Q000235:genetics; D001794:Blood Pressure; D015820:Cadherins / Q000235:genetics; D002460:Cell Line; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism*; D018076:DNA, Complementary; D004730:Endothelium, Vascular / Q000378:metabolism*; D018390:Gene Targeting; D018014:Gene Transfer Techniques; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000096:biosynthesis*; D006973:Hypertension / Q000378:metabolism*; D016086:Lentivirus; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D010084:Oxidation-Reduction; D010766:Phosphorylation; D011401:Promoter Regions, Genetic; D011507:Proteinuria / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013481:Superoxides / Q000378:metabolism; D014664:Vasodilation; D000099152:Cadherin 5
chemical_list: D055372:AMP-Activated Protein Kinases; D000109:Acetylcholine; D015703:Antigens, CD; D015820:Cadherins; D003577:Cytochrome P-450 Enzyme System; D018076:DNA, Complementary; D006893:Hydroxyeicosatetraenoic Acids; D052250:Nitric Oxide Synthase Type III; D051057:Proto-Oncogene Proteins c-akt; D013481:Superoxides; D000099152:Cadherin 5; C055987:20-hydroxy-5,8,11,14-eicosatetraenoic acid; C465388:cytochrome P-450 CYP4A2 (rat)
references.citation: Science. 1991 Feb 15;251(4995):799-802
references.pmid: 1846705
references.citation: Am J Physiol Renal Physiol. 2007 Aug;293(2):F501-5
references.pmid: 17507602
references.citation: Hypertension. 2005 Apr;45(4):643-8
references.pmid: 15723968
references.citation: Science. 1989 Jan 20;243(4889):388-90
references.pmid: 2492116
references.citation: Shock. 2008 Sep;30(3):329-35
references.pmid: 18323740
references.citation: Am J Physiol. 1998 Aug;275(2):R426-38
references.pmid: 9688677
references.citation: Antioxid Redox Signal. 2007 Dec;9(12):2065-74
references.pmid: 17883332
references.citation: J Pharmacol Exp Ther. 2008 Jan;324(1):103-10
references.pmid: 17947496
references.citation: J Appl Physiol (1985). 2002 Jul;93(1):330-7
references.pmid: 12070222
references.citation: Kidney Int. 2007 Jun;71(11):1105-15
references.pmid: 17361113
references.citation: Kidney Int. 2009 Mar;75(5):511-7
references.pmid: 19052533
references.citation: Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2455-65
references.pmid: 18952718
references.citation: Hypertension. 1996 Mar;27(3 Pt 2):564-8
references.pmid: 8613204
references.citation: Am J Physiol Renal Physiol. 2008 Dec;295(6):F1764-77
references.pmid: 18842817
references.citation: Blood. 1999 Jan 1;93(1):184-92
references.pmid: 9864160
references.citation: J Cell Biol. 1992 Sep;118(6):1511-22
references.pmid: 1522121
references.citation: Am J Physiol Regul Integr Comp Physiol. 2002 Jul;283(1):R60-8
references.pmid: 12069931
references.citation: Hypertension. 2000 Oct;36(4):604-9
references.pmid: 11040243
references.citation: J Pharmacol Exp Ther. 2007 Apr;321(1):18-27
references.pmid: 17210799
references.citation: Circulation. 2003 Feb 4;107(4):574-8
references.pmid: 12566369
references.citation: J Am Soc Nephrol. 2008 Apr;19(4):714-21
references.pmid: 18235092
references.citation: Am J Physiol. 1994 Jun;266(6 Pt 1):C1775-82
references.pmid: 8023907
references.citation: Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H1018-26
references.pmid: 18156192
references.citation: Am J Physiol Renal Physiol. 2003 Jan;284(1):F51-6
references.pmid: 12388396
references.citation: Pharmacol Rep. 2008 Jan-Feb;60(1):29-37
references.pmid: 18276983
references.citation: Circ Res. 1998 Nov 30;83(11):1069-79
references.pmid: 9831701
references.citation: Hypertension. 2007 Jul;50(1):123-9
references.pmid: 17548721
references.citation: Hypertension. 2008 May;51(5):1393-8
references.pmid: 18391101
references.citation: Hypertension. 2008 Mar;51(3):767-72
references.pmid: 18227405
references.citation: Am J Physiol Regul Integr Comp Physiol. 2003 Apr;284(4):R1055-62
references.pmid: 12531784
references.citation: Am J Physiol Heart Circ Physiol. 2000 May;278(5):H1517-26
references.pmid: 10775129
references.citation: Br J Pharmacol. 2001 Jun;133(3):325-9
references.pmid: 11375247
references.citation: Hypertension. 2000 Jan;35(1 Pt 2):457-63
references.pmid: 10642341
references.citation: Am J Physiol. 1997 Jul;273(1 Pt 2):R293-300
references.pmid: 9249563
references.citation: Am J Physiol Regul Integr Comp Physiol. 2001 Jan;280(1):R255-61
references.pmid: 11124159
references.citation: J Clin Invest. 1997 Nov 1;100(9):2153-7
references.pmid: 9410891
references.citation: Circ Res. 1993 Jan;72(1):126-36
references.pmid: 8417836
references.citation: J Clin Invest. 1997 Mar 15;99(6):1224-30
references.pmid: 9077530
references.citation: Circ Res. 2006 Apr 14;98(7):962-9
references.pmid: 16543501
references.citation: Circ Res. 1991 Apr;68(4):1154-63
references.pmid: 1901255
references.citation: Am J Physiol. 1999 Oct;277(4):H1546-52
references.pmid: 10516194
references.citation: Am J Physiol. 1996 Jan;270(1 Pt 2):R228-37
references.pmid: 8769806
references.citation: Circulation. 2004 Jul 27;110(4):438-43
references.pmid: 15262846
references.citation: J Pharmacol Exp Ther. 1998 Mar;284(3):966-73
references.pmid: 9495856
references.citation: Hypertension. 1993 Jun;21(6 Pt 2):985-8
references.pmid: 8505111
references.citation: Hypertension. 2004 Apr;43(4):860-5
references.pmid: 14967839
references.citation: Kidney Int. 2009 Jun;75(12):1288-1296
references.pmid: 19279555
references.citation: J Biol Chem. 2007 Jul 13;282(28):20351-64
references.pmid: 17519230
references.citation: Hypertension. 2001 Dec 1;38(6):1311-5
references.pmid: 11751709
references.citation: Am J Physiol Renal Physiol. 2002 Jul;283(1):F60-7
references.pmid: 12060587
references.citation: Circ Res. 1996 Jul;79(1):54-61
references.pmid: 8925569
references.citation: Am J Physiol Regul Integr Comp Physiol. 2002 Sep;283(3):R710-20
references.pmid: 12185006
references.citation: Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5211-6
references.pmid: 11320253
references.citation: J Pharmacol Exp Ther. 1989 Jan;248(1):229-32
references.pmid: 2492340
references.citation: Curr Drug Metab. 2004 Jun;5(3):245-56
references.pmid: 15180494
references.citation: Exp Physiol. 2005 Sep;90(5):783-90
references.pmid: 16049057
references.citation: Am J Physiol. 1999 Feb;276(2):F246-53
references.pmid: 9950955
references.citation: Am J Hypertens. 2001 Jun;14(6 Pt 2):90S-97S
references.pmid: 11411771
references.citation: Free Radic Biol Med. 2005 Apr 15;38(8):1032-6
references.pmid: 15780761
references.citation: Hypertension. 1993 Sep;22(3):357-64
references.pmid: 8349328